Merck & Co expands the portfolio of anticarcinogenic preparations at the expense of the transaction from Seattle Genetics Inc

@Farmatsevticheskij vestnik
#Accidents
Show original
Companies together will be engaged in development and sale a preparation ladiratuzumab...
Full text at the source
Analysis
×
Organizations
Organization Ranking